Has Antonio Fontelonga received payments from drug or device companies?

Yes. Drug and device makers reported $6,252 in general payments to Antonio Fontelonga across 245 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Antonio Fontelonga did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Antonio Fontelonga come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Antonio Fontelonga

Hematology & Oncology · Reno, NVNPI 1437164100

Payments from drug & device makers

$6,252in general payments, 2019–2025

Across 245 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$1K
AstraZeneca$903
Merck$712
GSK$441
Incyte Corporation$429
AVEO Pharmaceuticals, Inc.$264
plus $2K from 36 others

What the payments were for

Food & beverage$5,48988%
Education$76312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	32	$1,086
AstraZeneca(2 entities)	28	$903
Merck	35	$712
GSK	21	$441
Incyte Corporation	10	$429
AVEO Pharmaceuticals, Inc.	7	$264
Novartis	12	$232
Gilead(2 entities)	7	$211
Lilly USA, LLC	12	$206
Regeneron Healthcare Solutions, Inc.	6	$136
AbbVie	6	$126
Takeda Pharmaceuticals U.S.A., Inc.	7	$121
Seagen Inc.	3	$113
Karyopharm Therapeutics Inc.	4	$97
Beone Medicines USA, Inc.	4	$86
Bristol Myers Squibb	5	$80
Pfizer	4	$78
Bayer	4	$70
Puma Biotechnology, Inc.	3	$62
Boehringer Ingelheim	3	$62
Sanofi	2	$60
Eisai Inc.	3	$60
Pharmacosmos Therapeutics Inc.	2	$56
Daiichi Sankyo Inc.	2	$47
Beigene USA, Inc.	2	$43
EMD Serono, Inc.	2	$43
Caris MPI, Inc.	2	$43
Exelixis Inc.	2	$42
Amgen	2	$37
Geron Corporation	1	$34
Sobi, Inc	1	$34
Blue Earth Diagnostics	1	$28
Myriad Genetic Laboratories, Inc.	1	$26
Adaptive Biotechnologies Corporation	1	$25
Stemline Therapeutics Inc.	1	$25
Servier Pharmaceuticals LLC	1	$25
Mirati Therapeutics, Inc.	1	$21
E.r. Squibb & Sons, L.L.C.	1	$21
Tactile Systems Technology Inc	1	$19
Urogen Pharma, Inc.	1	$17
Accord Healthcare, Inc.	1	$16
Coherus Oncology, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,252 in reported general payments places this provider in the 25th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024

$1,527,078

Medicare patients

197

Services billed

48,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ImbruvicaIbrutinib	13	$211,277
Abiraterone Acetate	26	$27,032
Exemestane	18	$3,067
Anastrozole	88	$2,180
Letrozole	23	$1,250
Hydroxyurea	41	$1,018
Tamoxifen Citrate	18	$536
Dexamethasone	12	$170
Levothyroxine Sodium	29	$120
Prednisone	15	$64

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →